Ezivac%25252525252520enema

# Ezivac Enema ## Overview Ezivac enema is a proprietary brand formulation typically containing **Sodium Picosulfate** (or similar stimulant laxative/osmotic combinations depending on regional distribution). It acts locally in the colon to stimulate peristalsis or draw water into the bowel to facilitate evacuation. ## Primary Indications * Bowel preparation for colonoscopy, radiography, or surgical procedures. * Treatment of acute constipation (short-term use only). ## Adult Dosing Standard preparation often involves one enema (typically 120 mL – 130 mL) administered rectally as a single dose 1–2 hours before the intended procedure or as needed for constipation. Follow specific product labeling, as volume depends on the local formulation. ## Pediatric Dosing Safety and efficacy in children are not well established for all formulations. Generally, use is restricted to children >12 years of age at the adult dose. For younger patients, use only under strict pediatric gastroenterology supervision; doses are typically reduced or weight-based per local hospital protocol. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Avoid in severe renal failure due to the risk of electrolyte disturbances (hyperphosphatemia, hypocalcemia, or hypernatremia). * **Hepatic Impairment:** No specific adjustment, but use caution due to potential for electrolyte shifts. ## Contraindications * Known hypersensitivity to any component (e.g., sodium picosulfate, parabens). * Bowel obstruction or perforation. * Toxic megacolon or acute surgical abdomen. * Inflammatory bowel disease (ulcerative colitis, Crohn’s disease). * Severe dehydration or electrolyte imbalance. ## Adverse Effects * Rectal irritation, burning, or mucosal injury. * Abdominal cramping, nausea, vomiting. * Electrolyte imbalances (specifically hypernatremia or hypokalemia with excessive use). * Potential for dependency with chronic rectal stimulant use. ## Key Drug Interactions * **Diuretics:** Increased risk of electrolyte imbalance or dehydration. * **Nephrotoxic agents:** NSAIDs or ACE inhibitors may increase risk of acute kidney injury if dehydration occurs. * **Oral Medications:** Rapid bowel transit may decrease the absorption of oral medications taken close to the time of enema administration. ## Monitoring * Baseline electrolyte panel (if used over multiple days or in high-risk patients). * Monitor for signs of dehydration (dizziness, thirst, decreased urine output). * Observe for rectal bleeding or failure to evacuate. ## Clinical Pearls * Ensure the patient is in the left lateral decubitus position for optimal administration. * Advise patients to retain the enema for as long as possible (usually 5–15 minutes) to ensure efficacy. * **Do not use** as a chronic treatment for constipation; persistent constipation requires evaluation for underlying structural or transit disorders. * If no bowel movement occurs within 30–60 minutes of administration, the patient should contact their healthcare provider. *** *Disclaimer: This information is for educational purposes only. Clinical practice protocols vary by region and institution. Always verify specific dosing, safety profile, and contraindications by consulting the official product monograph or your local pharmacy department before prescribing or administering.*